# Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis

> **NCT00493324** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 43 (actual)

## Conditions studied

- Chronic Plaque Psoriasis

## Interventions

- **DRUG:** alefacept
- **DRUG:** polyvalent pneumococcal vaccine

## Key facts

- **NCT ID:** NCT00493324
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2012-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00493324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00493324, "Study to Evaluate the Immune Response to Pneumococcal Vaccine in Alefacept-treated Adults With Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00493324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*